CUMYL-BC-HPMEGACLONE-221
Identifiers | |
---|---|
IUPAC name
| |
Chemical and physical data | |
Formula | C28H30N2O |
Molar mass | 410.561 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
|
Cumyl-BC-HpMeGaClone-221 (Cumyl-BC[2.2.1]HpMeGaClone, SGT-271) is a gamma-carboline derivative which is a synthetic cannabinoid that has been sold as a designer drug. It was first identified in Germany in September 2020.[1]
See also
References
- ↑ European Monitoring Center for Drugs and Drug Addiction (December 2020). "New psychoactive substances: global markets, glocal threats and the COVID-19 pandemic. An update from the EU Early Warning System" (PDF). Luxembourg: Publications Office of the European Union. doi:10.2810/921262.
{{cite journal}}
: Cite journal requires|journal=
(help)
Phytocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Synthetic cannabinoid receptor agonists / neocannabinoids |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Allosteric CBR ligands |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Endocannabinoid enhancers (inactivation inhibitors) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
Anticannabinoids (antagonists/inverse agonists/antibodies) |
| ||||||||||||||||||||||||||||||||||||||||||||||||||
|
Receptor (ligands) |
| ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Transporter (modulators) |
| ||||||||||||
Enzyme (modulators) |
| ||||||||||||
Others |
| ||||||||||||
|
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.